Texas Diabetes & Endocrinology, PA Trials

Texas Diabetes & Endocrinology, PA	Welcome, Profile Billing Logout

56 Trials

Active Trials Industry lead sponsorIndustry collaborator

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Jones, Thomas I

NCT05706506: A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)

Completed

152

Tirzepatide, LY3298176

Eli Lilly and Company

Type 2 Diabetes, Diabetes Mellitus, Type 2

10/23

NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting

16700

Europe, Canada, Japan, US, RoW

Lepodisiran Sodium, LY3819469, Placebo

Eli Lilly and Company

Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)

03/29

NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting

10000

Europe, Canada, US, RoW

Retatrutide, LY3437943, Placebo

Eli Lilly and Company

Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)

02/29

QWINT-5, NCT05463744: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

Completed

692

Europe, Japan, US, RoW

Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec

Eli Lilly and Company

Type 1 Diabetes, Diabetes

05/24

CATT1, NCT06334133: Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

Recruiting

150

Cadisegliatin 800 mg QD, TTP399, Cadisegliatin 800 mg BID, Placebo

vTv Therapeutics

Diabetes Mellitus, Type 1

09/26

10/26

ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting

2749

Europe, US, RoW

Orforglipron, LY3502970, Insulin Glargine

Eli Lilly and Company

Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease

03/26

ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting

3127

Europe, Japan, US, RoW

Orforglipron, LY3502970, Placebo

Eli Lilly and Company

Obesity, Overweight, Overweight or Obesity

07/25

10/27

ZONE, NCT05762107: A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

Recruiting

186

Canada, US

Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg

Zucara Therapeutics Inc.

Type 1 Diabetes Mellitus with Hypoglycemia

06/25

07/25

ASCENT ASD, NCT04591392: Safety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD

Active, not recruiting

N/A

250

Europe, Canada, US

reSept ASD Occluder

atHeart Medical

Heart Septal Defect, Heart Septal Defects, Atrial, Heart Defects, Congenital, Cardiovascular Abnormalities, Cardiovascular Diseases, Heart Diseases, Congenital Abnormalities

03/27

03/32

NCT05325294: Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev®

Completed

N/A

244

MiniMed 780G System

Medtronic Diabetes, Eli Lilly and Company

Type 1 Diabetes

01/24

NCT05238142: In-Home Study With MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 Diabetes

Completed

N/A

574

MiniMed™ 780G Insulin Pump system

Medtronic Diabetes

Type 2 Diabetes Treated With Insulin

01/25

Blevins, Thomas C

NCT05706506: A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)

Completed

152

Tirzepatide, LY3298176

Eli Lilly and Company

Type 2 Diabetes, Diabetes Mellitus, Type 2

10/23

MKC-TI-193, NCT05904743: INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes

Completed

141

Afrezza, Technosphere Insulin, insulin degludec, Rapid-acting Insulin Analog, any FDA approved Rapid-acting Insulin Analog, Basal Insulin, any FDA approved Basal Insulin

Mannkind Corporation, Jaeb Center for Health Research

Diabetes Mellitus, Type 1

03/24

06/24

QWINT-4, NCT05462756 / 2021-005878-25: A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

Completed

730

Europe, US, RoW

Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Lispro (U100), Humalog, Insulin Glargine (U100), Basaglar

Eli Lilly and Company, Eli Lilly and Company

Type 2 Diabetes, Type 2 Diabetes Treated With Insulin

02/24

PALISADE, NCT05089084 / 2021-003680-10: Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

Active, not recruiting

Europe, Canada, Japan, US, RoW

Plozasiran, ARO-APOC3, Placebo

Arrowhead Pharmaceuticals

Familial Chylomicronemia

04/24

04/26

QWINT-5, NCT05463744: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

Completed

692

Europe, Japan, US, RoW

Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec

Eli Lilly and Company

Type 1 Diabetes, Diabetes

05/24

SURPASS-T1D-1, NCT06914895: A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

Recruiting

905

Europe, Japan, US, RoW

Tirzepatide, LY3298176, Placebo

Eli Lilly and Company

Type 1 Diabetes, Obesity, Overweight

05/27

ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting

3127

Europe, Japan, US, RoW

Orforglipron, LY3502970, Placebo

Eli Lilly and Company

Obesity, Overweight, Overweight or Obesity

07/25

10/27

TRIUMPH-3, NCT05882045: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Active, not recruiting

1800

Europe, Canada, US, RoW

Retatrutide, LY3437943, Placebo

Eli Lilly and Company

Obesity, Cardiovascular Diseases

04/26

05/26

SECURE-T2D, NCT05815342: OP5-005 Using Omnipod 5 in Adults With Type 2

Completed

N/A

343

Omnipod 5 Automated Glucose Control System

Insulet Corporation, Jaeb Center for Health Research

Type2 Diabetes

03/24

2IQP, NCT05785832: A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes

Completed

N/A

319

Canada, US

t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM, Standard Therapy plus continuous glucose monitoring (CGM)

Tandem Diabetes Care, Inc., Jaeb Center for Health Research

Type 2 Diabetes Treated With Insulin

09/24

NCT06853990: Innovative Automated Insulin Delivery System for Type 2 Diabetes

Recruiting

N/A

300

twiist insulin delivery system

Deka Research and Development, Sequel Med Tech

Type 2 Diabetes, Insulin Treated Type 2 Diabetes Mellitus

04/26

06/26

Horowitz, Barry M

SURPASS-SWITCH, NCT05564039: A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide

Completed

282

Europe, US, RoW

Tirzepatide, LY3298176, Dulaglutide, LY2189265

Eli Lilly and Company

Type 2 Diabetes

07/24

08/24

DREAM-T2D, NCT04854512 / 2020-000763-23: Investigational Study of Delayed Release Metformin

Suspended

675

Europe, Canada, US, RoW

Metformin DR, ANJ900, MetDR, Metformin IR, Metformin DR Placebo, Metformin IR placebo

Anji Pharma

Diabetes Mellitus, Type 2

12/23

06/24

CATT1, NCT06334133: Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

Recruiting

150

Cadisegliatin 800 mg QD, TTP399, Cadisegliatin 800 mg BID, Placebo

vTv Therapeutics

Diabetes Mellitus, Type 1

09/26

10/26

TRIUMPH-6, NCT06859268: A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

Active, not recruiting

643

Europe, Canada, US

Retatrutide, LY3437943, Placebo

Eli Lilly and Company

Obesity

04/28

ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting

2749

Europe, US, RoW

Orforglipron, LY3502970, Insulin Glargine

Eli Lilly and Company

Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease

03/26

SURPASS-T1D-2, NCT06962280: A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight

Recruiting

465

Europe, Canada, US, RoW

Tirzepatide, LY3298176, Placebo

Eli Lilly and Company

Type 1 Diabetes, Obesity, Overweight

04/27

12/27

ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Completed

1698

Japan, US, RoW

Orforglipron, LY3502970, Semaglutide

Eli Lilly and Company

Type 2 Diabetes

08/25

SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting

15374

Europe, Canada, Japan, US, RoW

Tirzepatide, LY3298176, Placebo

Eli Lilly and Company

Obesity, Overweight

10/27

OPTI-2, NCT06238778: Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec

Active, not recruiting

227

HDV-Lispro, HDV-L, Lispro, LIS

Diasome Pharmaceuticlas, Inc.

Diabetes Mellitus, Type 1

10/25

12/25

ZONE, NCT05762107: A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

Recruiting

186

Canada, US

Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg

Zucara Therapeutics Inc.

Type 1 Diabetes Mellitus with Hypoglycemia

06/25

07/25

NEPTUNE-17, NCT05838755: A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain

Terminated

147

Europe, Canada, Japan, US, RoW

GSK3858279, Placebo

GlaxoSmithKline

Pain

10/24

02/25

HORIZON, NCT05583344 / 2022-002538-14: Phase 2b Study of GSK4532990 in Adults With NASH

Active, not recruiting

284

Europe, Canada, Japan, US, RoW

GSK4532990, Placebo

GlaxoSmithKline, GlaxoSmithKline Research & Development Limited

Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease

02/26

04/27

SECURE-T2D, NCT05815342: OP5-005 Using Omnipod 5 in Adults With Type 2

Completed

N/A

343

Omnipod 5 Automated Glucose Control System

Insulet Corporation, Jaeb Center for Health Research

Type2 Diabetes

03/24

PRIZETAG, NCT06567795: PRimary IndividualiZed Evaluation of Cardiovascular Events in Patients With Diabetes Mellitus Using hemoTAG

Recruiting

N/A

189

Hemotag

Aventusoft, LLC., National Heart, Lung, and Blood Institute (NHLBI)

Diabetes Mellitus Type 2, Cardiovascular Diseases, Coronary Artery Disease, Cerebrovascular Disease, Peripheral Artery Disease

03/26

03/27

Harrison, Lindsay B

ARGON-2, NCT04378010 / 2019-003876-38: A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

Terminated

Europe, Canada, US, RoW

EDP-305 1.5 mg, EDP-305, EDP-305 2 mg, Placebo

Enanta Pharmaceuticals, Inc, Enanta Pharmaceuticals, Inc.

Non-Alcoholic Steatohepatitis

10/21

11/21

NCT05325294: Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev®

Completed

N/A

244

MiniMed 780G System

Medtronic Diabetes, Eli Lilly and Company

Type 1 Diabetes

01/24

Fields, Cory

ZONE, NCT05762107: A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

Recruiting

186

Canada, US

Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg

Zucara Therapeutics Inc.

Type 1 Diabetes Mellitus with Hypoglycemia

06/25

07/25

NCT06719531: SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients With Type 1 and Type 2 Diabetes

Withdrawn

N/A

1500

Continuous Glucose Monitoring

Medtronic Diabetes

Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus

12/25

Chen, Jean

ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting

2749

Europe, US, RoW

Orforglipron, LY3502970, Insulin Glargine

Eli Lilly and Company

Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease

03/26

SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting

15374

Europe, Canada, Japan, US, RoW

Tirzepatide, LY3298176, Placebo

Eli Lilly and Company

Obesity, Overweight

10/27

OPTI-2, NCT06238778: Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec

Active, not recruiting

227

HDV-Lispro, HDV-L, Lispro, LIS

Diasome Pharmaceuticlas, Inc.

Diabetes Mellitus, Type 1

10/25

12/25

ZONE, NCT05762107: A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

Recruiting

186

Canada, US

Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg

Zucara Therapeutics Inc.

Type 1 Diabetes Mellitus with Hypoglycemia

06/25

07/25

NCT07215312: A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin

Not yet recruiting

100

US, RoW

LY3938577, Degludec

Eli Lilly and Company

Diabetes Mellitus, Type 2

11/26

12/26

NCT06783309: CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)

Recruiting

1/2

CNP-103, Treatment, Placebo

COUR Pharmaceutical Development Company, Inc.

Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus, Type 1 Diabetes in Adolescence, Type 1 Diabetes in Children, Type 1 Diabetes (Juvenile Onset), Type 1 Diabetes, Type 1 Diabetes Patients, Type 1 Diabetes Mellitis

12/26

06/27

NCT06273124: Investigational Extended Wear Insulin Infusion Set in People With Type 1 Diabetes

Completed

N/A

260

SteadiSet Extended Wear Infusion Set

Tandem Diabetes Care, Inc., Jaeb Center for Health Research

Type1diabetes

12/24

NCT06719531: SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients With Type 1 and Type 2 Diabetes

Withdrawn

N/A

1500

Continuous Glucose Monitoring

Medtronic Diabetes

Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus

12/25

NA-PAS, NCT04836546: Eversense® Non-adjunctive Use Post Approval Study

Active, not recruiting

N/A

925

Blood glucose meter, Eversense CGM System

Senseonics, Inc.

Diabetes

03/26

Alexander, Lindsay M

ZONE, NCT05762107: A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

Recruiting

186

Canada, US

Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg

Zucara Therapeutics Inc.

Type 1 Diabetes Mellitus with Hypoglycemia

06/25

07/25

SECURE-T2D, NCT05815342: OP5-005 Using Omnipod 5 in Adults With Type 2

Completed

N/A

343

Omnipod 5 Automated Glucose Control System

Insulet Corporation, Jaeb Center for Health Research

Type2 Diabetes

03/24

NCT05325294: Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev®

Completed

N/A

244

MiniMed 780G System

Medtronic Diabetes, Eli Lilly and Company

Type 1 Diabetes

01/24

NCT05238142: In-Home Study With MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 Diabetes

Completed

N/A

574

MiniMed™ 780G Insulin Pump system

Medtronic Diabetes

Type 2 Diabetes Treated With Insulin

01/25

Dunn, Mari

ZONE, NCT05762107: A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

Recruiting

186

Canada, US

Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg

Zucara Therapeutics Inc.

Type 1 Diabetes Mellitus with Hypoglycemia

06/25

07/25

Bohanan, Kathy

ZONE, NCT05762107: A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

Recruiting

186

Canada, US

Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg

Zucara Therapeutics Inc.

Type 1 Diabetes Mellitus with Hypoglycemia

06/25

07/25

NCT06853990: Innovative Automated Insulin Delivery System for Type 2 Diabetes

Recruiting

N/A

300

twiist insulin delivery system

Deka Research and Development, Sequel Med Tech

Type 2 Diabetes, Insulin Treated Type 2 Diabetes Mellitus

04/26

06/26

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Jones, Thomas I

NCT05706506: A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)

Completed

152

Tirzepatide, LY3298176

Eli Lilly and Company

Type 2 Diabetes, Diabetes Mellitus, Type 2

10/23

NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting

16700

Europe, Canada, Japan, US, RoW

Lepodisiran Sodium, LY3819469, Placebo

Eli Lilly and Company

Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)

03/29

NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting

10000

Europe, Canada, US, RoW

Retatrutide, LY3437943, Placebo

Eli Lilly and Company

Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)

02/29

QWINT-5, NCT05463744: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

Completed

692

Europe, Japan, US, RoW

Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec

Eli Lilly and Company

Type 1 Diabetes, Diabetes

05/24

CATT1, NCT06334133: Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

Recruiting

150

Cadisegliatin 800 mg QD, TTP399, Cadisegliatin 800 mg BID, Placebo

vTv Therapeutics

Diabetes Mellitus, Type 1

09/26

10/26

ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting

2749

Europe, US, RoW

Orforglipron, LY3502970, Insulin Glargine

Eli Lilly and Company

Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease

03/26

ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting

3127

Europe, Japan, US, RoW

Orforglipron, LY3502970, Placebo

Eli Lilly and Company

Obesity, Overweight, Overweight or Obesity

07/25

10/27

ZONE, NCT05762107: A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

Recruiting

186

Canada, US

Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg

Zucara Therapeutics Inc.

Type 1 Diabetes Mellitus with Hypoglycemia

06/25

07/25

ASCENT ASD, NCT04591392: Safety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD

Active, not recruiting

N/A

250

Europe, Canada, US

reSept ASD Occluder

atHeart Medical

Heart Septal Defect, Heart Septal Defects, Atrial, Heart Defects, Congenital, Cardiovascular Abnormalities, Cardiovascular Diseases, Heart Diseases, Congenital Abnormalities

03/27

03/32

NCT05325294: Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev®

Completed

N/A

244

MiniMed 780G System

Medtronic Diabetes, Eli Lilly and Company

Type 1 Diabetes

01/24

NCT05238142: In-Home Study With MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 Diabetes

Completed

N/A

574

MiniMed™ 780G Insulin Pump system

Medtronic Diabetes

Type 2 Diabetes Treated With Insulin

01/25

Blevins, Thomas C

NCT05706506: A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)

Completed

152

Tirzepatide, LY3298176

Eli Lilly and Company

Type 2 Diabetes, Diabetes Mellitus, Type 2

10/23

MKC-TI-193, NCT05904743: INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes

Completed

141

Afrezza, Technosphere Insulin, insulin degludec, Rapid-acting Insulin Analog, any FDA approved Rapid-acting Insulin Analog, Basal Insulin, any FDA approved Basal Insulin

Mannkind Corporation, Jaeb Center for Health Research

Diabetes Mellitus, Type 1

03/24

06/24

Completed

730

Europe, US, RoW

Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Lispro (U100), Humalog, Insulin Glargine (U100), Basaglar

Eli Lilly and Company, Eli Lilly and Company

Type 2 Diabetes, Type 2 Diabetes Treated With Insulin

02/24

PALISADE, NCT05089084 / 2021-003680-10: Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

Active, not recruiting

Europe, Canada, Japan, US, RoW

Plozasiran, ARO-APOC3, Placebo

Arrowhead Pharmaceuticals

Familial Chylomicronemia

04/24

04/26

QWINT-5, NCT05463744: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

Completed

692

Europe, Japan, US, RoW

Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec

Eli Lilly and Company

Type 1 Diabetes, Diabetes

05/24

SURPASS-T1D-1, NCT06914895: A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

Recruiting

905

Europe, Japan, US, RoW

Tirzepatide, LY3298176, Placebo

Eli Lilly and Company

Type 1 Diabetes, Obesity, Overweight

05/27

ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting

3127

Europe, Japan, US, RoW

Orforglipron, LY3502970, Placebo

Eli Lilly and Company

Obesity, Overweight, Overweight or Obesity

07/25

10/27

TRIUMPH-3, NCT05882045: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Active, not recruiting

1800

Europe, Canada, US, RoW

Retatrutide, LY3437943, Placebo

Eli Lilly and Company

Obesity, Cardiovascular Diseases

04/26

05/26

SECURE-T2D, NCT05815342: OP5-005 Using Omnipod 5 in Adults With Type 2

Completed

N/A

343

Omnipod 5 Automated Glucose Control System

Insulet Corporation, Jaeb Center for Health Research

Type2 Diabetes

03/24

2IQP, NCT05785832: A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes

Completed

N/A

319

Canada, US

t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM, Standard Therapy plus continuous glucose monitoring (CGM)

Tandem Diabetes Care, Inc., Jaeb Center for Health Research

Type 2 Diabetes Treated With Insulin

09/24

NCT06853990: Innovative Automated Insulin Delivery System for Type 2 Diabetes

Recruiting

N/A

300

twiist insulin delivery system

Deka Research and Development, Sequel Med Tech

Type 2 Diabetes, Insulin Treated Type 2 Diabetes Mellitus

04/26

06/26

Horowitz, Barry M

SURPASS-SWITCH, NCT05564039: A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide

Completed

282

Europe, US, RoW

Tirzepatide, LY3298176, Dulaglutide, LY2189265

Eli Lilly and Company

Type 2 Diabetes

07/24

08/24

DREAM-T2D, NCT04854512 / 2020-000763-23: Investigational Study of Delayed Release Metformin

Suspended

675

Europe, Canada, US, RoW

Metformin DR, ANJ900, MetDR, Metformin IR, Metformin DR Placebo, Metformin IR placebo

Anji Pharma

Diabetes Mellitus, Type 2

12/23

06/24

CATT1, NCT06334133: Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

Recruiting

150

Cadisegliatin 800 mg QD, TTP399, Cadisegliatin 800 mg BID, Placebo

vTv Therapeutics

Diabetes Mellitus, Type 1

09/26

10/26

TRIUMPH-6, NCT06859268: A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

Active, not recruiting

643

Europe, Canada, US

Retatrutide, LY3437943, Placebo

Eli Lilly and Company

Obesity

04/28

ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting

2749

Europe, US, RoW

Orforglipron, LY3502970, Insulin Glargine

Eli Lilly and Company

Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease

03/26

SURPASS-T1D-2, NCT06962280: A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight

Recruiting

465

Europe, Canada, US, RoW

Tirzepatide, LY3298176, Placebo

Eli Lilly and Company

Type 1 Diabetes, Obesity, Overweight

04/27

12/27

ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Completed

1698

Japan, US, RoW

Orforglipron, LY3502970, Semaglutide

Eli Lilly and Company

Type 2 Diabetes

08/25

SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting

15374

Europe, Canada, Japan, US, RoW

Tirzepatide, LY3298176, Placebo

Eli Lilly and Company

Obesity, Overweight

10/27

OPTI-2, NCT06238778: Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec

Active, not recruiting

227

HDV-Lispro, HDV-L, Lispro, LIS

Diasome Pharmaceuticlas, Inc.

Diabetes Mellitus, Type 1

10/25

12/25

ZONE, NCT05762107: A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

Recruiting

186

Canada, US

Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg

Zucara Therapeutics Inc.

Type 1 Diabetes Mellitus with Hypoglycemia

06/25

07/25

NEPTUNE-17, NCT05838755: A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain

Terminated

147

Europe, Canada, Japan, US, RoW

GSK3858279, Placebo

GlaxoSmithKline

Pain

10/24

02/25

HORIZON, NCT05583344 / 2022-002538-14: Phase 2b Study of GSK4532990 in Adults With NASH

Active, not recruiting

284

Europe, Canada, Japan, US, RoW

GSK4532990, Placebo

GlaxoSmithKline, GlaxoSmithKline Research & Development Limited

Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease

02/26

04/27

SECURE-T2D, NCT05815342: OP5-005 Using Omnipod 5 in Adults With Type 2

Completed

N/A

343

Omnipod 5 Automated Glucose Control System

Insulet Corporation, Jaeb Center for Health Research

Type2 Diabetes

03/24

PRIZETAG, NCT06567795: PRimary IndividualiZed Evaluation of Cardiovascular Events in Patients With Diabetes Mellitus Using hemoTAG

Recruiting

N/A

189

Hemotag

Aventusoft, LLC., National Heart, Lung, and Blood Institute (NHLBI)

Diabetes Mellitus Type 2, Cardiovascular Diseases, Coronary Artery Disease, Cerebrovascular Disease, Peripheral Artery Disease

03/26

03/27

Harrison, Lindsay B

ARGON-2, NCT04378010 / 2019-003876-38: A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

Terminated

Europe, Canada, US, RoW

EDP-305 1.5 mg, EDP-305, EDP-305 2 mg, Placebo

Enanta Pharmaceuticals, Inc, Enanta Pharmaceuticals, Inc.

Non-Alcoholic Steatohepatitis

10/21

11/21

NCT05325294: Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev®

Completed

N/A

244

MiniMed 780G System

Medtronic Diabetes, Eli Lilly and Company

Type 1 Diabetes

01/24

Fields, Cory

ZONE, NCT05762107: A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

Recruiting

186

Canada, US

Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg

Zucara Therapeutics Inc.

Type 1 Diabetes Mellitus with Hypoglycemia

06/25

07/25

NCT06719531: SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients With Type 1 and Type 2 Diabetes

Withdrawn

N/A

1500

Continuous Glucose Monitoring

Medtronic Diabetes

Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus

12/25

Chen, Jean

ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting

2749

Europe, US, RoW

Orforglipron, LY3502970, Insulin Glargine

Eli Lilly and Company

Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease

03/26

SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting

15374

Europe, Canada, Japan, US, RoW

Tirzepatide, LY3298176, Placebo

Eli Lilly and Company

Obesity, Overweight

10/27

OPTI-2, NCT06238778: Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec

Active, not recruiting

227

HDV-Lispro, HDV-L, Lispro, LIS

Diasome Pharmaceuticlas, Inc.

Diabetes Mellitus, Type 1

10/25

12/25

ZONE, NCT05762107: A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

Recruiting

186

Canada, US

Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg

Zucara Therapeutics Inc.

Type 1 Diabetes Mellitus with Hypoglycemia

06/25

07/25

NCT07215312: A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin

Not yet recruiting

100

US, RoW

LY3938577, Degludec

Eli Lilly and Company

Diabetes Mellitus, Type 2

11/26

12/26

NCT06783309: CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)

Recruiting

1/2

CNP-103, Treatment, Placebo

COUR Pharmaceutical Development Company, Inc.

12/26

06/27

NCT06273124: Investigational Extended Wear Insulin Infusion Set in People With Type 1 Diabetes

Completed

N/A

260

SteadiSet Extended Wear Infusion Set

Tandem Diabetes Care, Inc., Jaeb Center for Health Research

Type1diabetes

12/24

NCT06719531: SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients With Type 1 and Type 2 Diabetes

Withdrawn

N/A

1500

Continuous Glucose Monitoring

Medtronic Diabetes

Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus

12/25

NA-PAS, NCT04836546: Eversense® Non-adjunctive Use Post Approval Study

Active, not recruiting

N/A

925

Blood glucose meter, Eversense CGM System

Senseonics, Inc.

Diabetes

03/26

Alexander, Lindsay M

ZONE, NCT05762107: A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

Recruiting

186

Canada, US

Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg

Zucara Therapeutics Inc.

Type 1 Diabetes Mellitus with Hypoglycemia

06/25

07/25

SECURE-T2D, NCT05815342: OP5-005 Using Omnipod 5 in Adults With Type 2

Completed

N/A

343

Omnipod 5 Automated Glucose Control System

Insulet Corporation, Jaeb Center for Health Research

Type2 Diabetes

03/24

NCT05325294: Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev®

Completed

N/A

244

MiniMed 780G System

Medtronic Diabetes, Eli Lilly and Company

Type 1 Diabetes

01/24

NCT05238142: In-Home Study With MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 Diabetes

Completed

N/A

574

MiniMed™ 780G Insulin Pump system

Medtronic Diabetes

Type 2 Diabetes Treated With Insulin

01/25

Dunn, Mari

ZONE, NCT05762107: A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

Recruiting

186

Canada, US

Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg

Zucara Therapeutics Inc.

Type 1 Diabetes Mellitus with Hypoglycemia

06/25

07/25

Bohanan, Kathy

ZONE, NCT05762107: A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

Recruiting

186

Canada, US

Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg

Zucara Therapeutics Inc.

Type 1 Diabetes Mellitus with Hypoglycemia

06/25

07/25

NCT06853990: Innovative Automated Insulin Delivery System for Type 2 Diabetes

Recruiting

N/A

300

twiist insulin delivery system

Deka Research and Development, Sequel Med Tech

Type 2 Diabetes, Insulin Treated Type 2 Diabetes Mellitus

04/26

06/26

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites